Edition:
United States

NuCana PLC (NCNA.OQ)

NCNA.OQ on NASDAQ Stock Exchange Global Select Market

27.75USD
25 May 2018
Change (% chg)

$0.08 (+0.29%)
Prev Close
$27.67
Open
$27.93
Day's High
$28.00
Day's Low
$27.70
Volume
4,446
Avg. Vol
27,266
52-wk High
$30.03
52-wk Low
$9.48

Chart for

About

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentratio... (more)

Overall

Beta: --
Market Cap(Mil.): $880.21
Shares Outstanding(Mil.): 31.81
Dividend: --
Yield (%): --

Financials

  NCNA.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -0.97 -- --
ROI: -- -7.30 12.79
ROE: -- -10.05 14.67

BRIEF-NuCana Q1 Loss Per Share GBP 0.20

* Q1 LOSS PER SHARE GBP 0.20 Source text for Eikon: Further company coverage:

May 23 2018

BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer

* NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER

Jan 19 2018

Earnings vs. Estimates